Anthropics Push Into AI Drug Discovery and Medical Research

In July 2026, Claude Science indicated Anthropic's clear commitment to supporting healthcare organizations expedite research processes. The release of Claude Science has marked a new era for AI leader Anthropic as it positions itself as a critical tool for researchers engaged in drug discovery. AI has the potential to rapidly accelerate the pace of drug discovery and the development of healthcare interventions. With the release of Claude Science, this potential could soon evolve into a practical reality for all Claude paid subscribers.

Anthropic’s “AI workbench for scientists” aims to support medical researchers by providing open access to an AI agent equipped with more than 60 curated skills and connectors spanning a range of life science disciplines, all within an interface designed for the unique demands of scientific research. Anthropic will also leverage its new product to pursue its own research and drug development programs for rare and neglected diseases.

Although the launch of Claude Science marks a significant milestone in Anthropic’s healthcare capabilities, it is not the company’s first incursion into the space. In October 2025, Anthropic released Claude for Life Sciences, which is a suite of plug-ins and connectors that are linked to scientific research platforms that enabled the standard Claude LLM to support better medical researchers, clinical coordinators, and regulatory affairs managers.

Claude Science is significant as it is a standalone offering, placing it in the same bracket as the widely used Claude Code and Claude Cowork products, which indicates a clear signal that AI’s healthcare uses will be a core focus for Anthropic moving forward. Anthropic has also begun building its own specialized wet labs and strategically acquiring companies operating in the biotech space to bring practical expertise on running scientific programs in-house.

Impact on the Healthcare Market

Artificial intelligence (AI) is completely redefining modern medicine. From accelerating diagnoses to personalizing treatment plans, AI is set to tackle some of healthcare's most pressing challenges. AI technologies can process and synthesize data far more quickly than humans. This rapid analysis allows clinicians to gain actionable, personalized, and predictive insights for individual patients. For instance, AI can analyze a patient's medical history, pathology reports, and imaging scans in minutes to identify patterns and recommend tailored treatments.

Machine learning is also another advanced tool that enables systems to learn, adapt, and make inferences by identifying patterns in data. Deep learning is also a powerful subset of machine learning that mimics the way the human brain processes information to generate accurate insights and predictions. Natural language processing also enables machines to comprehend and generate human language and text. There is a rapidly growing number of AI-powered scientific discovery platforms aimed at helping researchers design experiments, analyze biological data, review literature, and accelerate drug discovery. The world’s biggest tech companies are harnessing the power of AI in order to compress R&D timelines and streamline scientific operations.

Impact on the Artificial Intelligence in Healthcare Market

The global artificial intelligence (AI) in healthcare market size is valued at USD 36.96 billion in 2025 and is predicted to increase from USD 51.20 billion in 2026 to approximately USD 744.34 billion by 2035, expanding at a CAGR of 35.02% from 2026 to 2035.

According to Precedence Research, the market is driven by the increasing need for efficient diagnostics, personalized medicine, and improved patient care delivery. This expansion is fueled by rising healthcare costs, the digitization of patient data (EHRs), and the prevalence of chronic diseases. The startup ecosystem is thriving, with intense innovation in machine learning algorithms for medical imaging analysis, natural language processing (NLP) for clinical documentation, and AI-driven personalized treatment plans, offering scalable, clinically validated solutions.

The growing demand for personalized medicines and the necessity of maintaining digital health records are significantly driving the artificial intelligence in healthcare market. The novel technologies like artificial intelligence and machine learning are now being integrated into the healthcare systems, which will allow health professionals to identify diseases early and offer enhanced care services to the patients. Moreover, the data analytics, deep learning technology, natural language processing (NPL), predictive analytics, and content analytics are supporting the healthcare professionals in early diagnosis and care services.

Impact on the Generative AI In Healthcare Market

The global generative AI in healthcare market size is valued at USD 2.64 billion in 2025 and is predicted to increase from USD 3.57 billion in 2026 to approximately USD 48.23 billion by 2035, expanding at a CAGR of 33.71% from 2026 to 2035.

According to Precedence Research, the market is driven by collaborative efforts between technology providers, healthcare institutions, and research organizations. These collaborations foster the exchange of knowledge, resources, and expertise, pushing the boundaries of generative AI applications in healthcare. Additionally, advancements in AI technologies, computational power, and data availability are likely to contribute to the growth and sophistication of generative AI solutions. This is expected to open opportunities for the growth of the market during the forecast period.

The applications of generative AI in healthcare are quite diverse and far-reaching. It can assist in predicting diseases, identifying risk factors, and improving diagnostic accuracy by analyzing large volumes of medical records. The market is being driven by several factors, including growing collaboration among the key players, technological advancements, and growing research and development activities.

Expert Opinion

• Emmanuel Frenehard, Chief Digital Officer at Sanofi, said:

“We're seeing efficiency gains across the value-chain, while our enterprise deployment has enhanced how teams work.

“This collaboration with Anthropic augments human expertise to deliver life-changing medicines faster to patients worldwide." 

• Louise Lind Skov, Director of Content Digitalisation at Novo Nordisk, explains:

"We've consistently been one of the first movers when it comes to document and content automation in pharma development. 

“Our work with Anthropic and Claude has set a new standard – we're not just automating tasks, we're transforming how medicines get from discovery to the patients who need them."